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1  | INTRODUC TION
Research in the past decade highlighted the importance of the gut 
microbiota to our health. There is a delicate interaction between the 
host and the microbiota, and the disruption of this balance can com‐
promise the homeostasis and survival of the entire human organism[7] 
and can contribute to the development of severe pathologies[36] 
The gut microbiome greatly influences the host immune system by 
providing protection against exogenous pathogens and by priming 
immunoprotective responses[60] Hence, an altered gut flora may 
contribute to the development of autoimmune and inflammatory 
diseases, even in organs distant from the gut, such as the skin.[60] 
Indeed, a growing body of evidence supports that intestinal dysbio‐
sis, a state of microbial imbalance, can almost invariably be observed 
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Abstract
The existence of a gut‐skin axis is supported by increasing evidence, but its transla‐
tional	potential	 is	not	widely	recognized.	Studies	linked	inflammatory	skin	diseases	
to an imbalanced gut microbiome; hence, the modulation of the gut microbiota to 
improve skin condition seems to be a feasible approach. Today, there is a growing 
interest in natural products as alternatives to synthetic drugs. In this respect, oral 
probiotics could be a simple, safe and cheap modality in the therapeutic management 
of skin inflammation. Unfortunately, very few studies have looked into how probiotic 
supplementation influences inflammatory skin disorders. The result, though promis‐
ing, are difficult to implement in clinical practice due to the heterogeneity of the 
applied	supplemental	regimen	in	the	different	studies.	In	this	Viewpoint,	we	aim	to	
encourage the conduction of more research in that direction to explore unambigu‐
ously the therapeutic potential of oral probiotics in dermatology. We focus on the 
most	common	inflammatory	skin	diseases	(atopic	dermatitis,	psoriasis,	rosacea,	acne	
vulgaris)	with	an	associated	gut	dysbiosis,	but	we	also	discuss	some	 less	common,	
but	very	serious	skin	pathologies	(eg	erythema	nodosum,	pyoderma	gangrenosum,	
hidradenitis	suppurativa)	that	are	possibly	 linked	to	a	disturbed	gut	flora	composi‐
tion. We dissect the possible mechanisms along the gut‐skin axis and highlight novel 
points where probiotics could interfere in this communication in the diseased state.
K E Y W O R D S
atopic dermatitis, inflammatory skin diseases, pathogenesis, psoriasis
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in common inflammatory skin pathologies, such as atopic dermatitis 
(AD)[58,91] psoriasis[51,112] rosacea[82] and acne vulgaris.[16] This reali‐
zation	gave	rise	to	the	recognition	of	the	gut‐skin	axis.	[62,86]	Actually,	
this	notion	is	not	a	new	one.	In	1930,	the	two	dermatologists,	John	
H.	Stokes	and	Donald	M.	Pillsbury,	proposed	their	groundbreaking	
theory about an interrelationship between emotional states, the 
intestinal flora and systemic and skin inflammation,[108] which was 
later unified as the gut‐brain[103] and the gut‐brain‐skin axis models[4] 
Most recently, similar crosstalk has also been postulated between 
the	gut	microbiome	and	the	 lungs	 (gut‐lung	axis)[23] or cancer cells 
(cancer‐gut	axis).[75]
Although	many	 reports	 associate	 the	 gut	microbiota	 compo‐
sition with human health and disease, the causative relationships 
remain to be elucidated. There is a need for manipulation strate‐
gies to clarify the involvement of the gut microbiome in diseases. 
These strategies may be the use of orally administered antibiotics, 
prebiotics, probiotics and most recently faecal transplantation.[76] 
Antibiotics	are	commonly	involved	in	the	management	of	cutane‐
ous inflammation, but their use should be limited, due to the risk of 
developing resistance. Though the concept of using faecal trans‐
plantation for treating abdominal diseases dates back to mediaeval 
China[45] faecal transplantation maturated into a medically ac‐
cepted approach only in the recent years as an effective treatment 
strategy in Clostridium difficile infection.[106] Though a promising 
treatment modality in gastrointestinal disorders associated with 
a disturbed gut flora and skin symptoms, faecal transplantation 
is unlikely to enter dermatology and cosmetology clinical practice 
rapidly. In terms of modulating the gut microbiome with potential 
beneficial effects on the skin, prebiotics represent an appealing 
set of compounds. Prebiotics are dietary components fermented 
by gut microbes, and nutritional elements that support the growth 
of	bacteria.	Among	others,	 prebiotics	 involve	 fructooligosaccha‐
rides, galactooligosaccharides, inulin, polydextrose, lactulose, sor‐
bitol or xylitol.[21]
Probiotics by definition are ‘live microorganisms, which, 
when consumed in adequate amounts, confer a health effect 
on the host’.[41]	 Actual	 health	 effects	 have	 been	 reported	 for	
specific strains of the following genera: anaerobic microbes: 
Lactobacillus, Bifidobacterium, Saccharomyces, Enterococcus, 
Streptococcus, Pediococcus, Leuconostoc, Escherichia coli; and the 
aerobic Bacillus strains.[38] The bacterial probiotic genera demon‐
strated to exert beneficial effects on skin health after oral appli‐
cation are the Bifidobacterium and Lactobacillus	(for	an	overview	
on the subject readers are referred to[97]. In an interesting 
paper	 Levkovich	 et al, reports that feeding mice with yogurt 
containing the probiotic Lactobacillus reuteri induces a general 
‘glow of health’ phenotype in the animals, which was character‐
ized	by	epithelial	follicular	shift	to	anagen	phase	with	increased	
folliculogenesis and sebocytogenesis resulting in thick, radiant 
fur. The probiotic strain exerted these effects through the mod‐
ulation of the immune system; the application of the probiotic 
increased the production of the anti‐inflammatory cytokine 
IL‐10	 that	 induced	 peripheral	 regulatory	 T	 (Treg)	 lymphocytes	
and the secretion of health‐stimulating hypothalamic hormones 
leading to improved epithelial integrity and immune toler‐
ance.[63] Unfortunately, the study does not go into detail if the 
application of the probiotic modulated the composition of the 
gut microbiota. Nor do we know, whether the observed phe‐
notype	can	be	generalized	after	probiotic	 consumption	or	 it	 is	
specific for Lactobacillus reuteri intake. Nevertheless, it is easy 
to	realize	that	benefits	gained	upon	probiotic	supplementation	
in mice would be a desirable improvement in human skin health, 
with obvious implications in the therapy of inflammatory skin 
conditions.
Currently, the recommendation of oral probiotics as a treat‐
ment	 or	 adjuvant	 strategy	 in	 skin	 disorders	 is	 not	 usual.	 Given	
that gut dysbiosis is commonly observed in skin pathologies, the 
crosstalk between gut and skin could offer targetable pathways 
with obvious therapeutic potential in dermatological practice. 
However, the molecular mechanism of the crosstalk is not well 
understood. The gut is considered as a major immune organ, with 
the	gut‐associated	lymphoid	tissue	(GALT)	being	the	most	complex	
immune	compartment.	Parts	of	the	GALT	are	Peyer's	patches	that	
are	 organized	 lymphoid	 tissues	 known	 as	 the	 primary	 inductive	
sites for the mucosal immune response.[3] It has long been demon‐
strated	that	dendritic	cells	of	the	Peyer's	patches	synthesize	IL‐10	
and induce the differentiation of T helper cells.[55] Cytokines and 
primed	immune	cells	from	the	Peyer's	patches	may	be	transported	
via the circulation to the skin, where they could modulate the im‐
mune status and improve defense mechanisms, providing a pos‐
sible link in the gut‐skin communication[9] Reports suggest that 
probiotics trigger immunomodulation through the components 
of	 the	 GALT,	 and	 the	 Peyer's	 patches	 may	 have	 special	 signifi‐
cance.[44] Contributing to our understanding of probiotic action, 
evidence has been presented that probiotics ameliorate intesti‐
nal inflammation by local stimulation of the gut epithelial innate 
immune responses.[88] The presented mechanism of probiotics in‐
volves the improvement of epithelial barrier function, increased 
production of TNF‐alpha by epithelial cells and activation of the 
NF‐kappaB pathway.[88]
Beyond immune modulation, one has to take into consideration 
that when we are talking about the microbiota of the gut, we are 
talking about probably trillions of microorganisms that obviously 
have huge metabolic capacity. The bioactive metabolites produced 
by bacteria upon interaction with dietary components are the most 
probable signalling links between the gut microbiota and the host.[28] 
Faecal and serum metabolomics should be conducted from patients 
with dermatological diseases to gain insight into the correlation of 
intestinal bacterial metabolism and skin condition. These analyses 
could help to better understand probiotic action, and to better de‐
sign probiotic application.
In this viewpoint essay, we dissect the possible mechanisms and 
pathways through which the gut and skin may communicate, and we 
try to shed light on the significance of these pathways in the path‐
omechanisms of the most common inflammatory skin diseases, and 
how probiotics may intervene in the gut‐skin axis.
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1.1 | Atopic dermatitis
Atopic	dermatitis	(AD)	or	eczema	is	a	chronic	inflammatory	skin	dis‐
ease where the initial symptoms commonly occur in the first 5 years 
of life, that affects about 20% of children in developed countries,[119] 
and	 the	 prevalence	 of	 adulthood	 AD	 is	 estimated	 around	 2%‐5%	
across different countries[6]	Skin	of	patients	with	AD	exhibits	a	sig‐
nificant barrier dysfunction, which is a result of a specific combi‐
nation of genetic and environmental factors.[22]	A	well‐established	
genetic determinant of skin barrier impairment is the deficiency of 
the structural protein filaggrin.[22]	Environmental	factors,	such	as	the	
use of hygienic products, may further exacerbate epidermal barrier 
disruption.[22]	Application	of	soaps	and	detergents	is	very	frequently	
associated with the appearance of irritant contact dermatitis on the 
hands,	which	can	aggravate	AD.[73] The negative effect of the use of 
soaps and detergents on skin is most possibly due to the consequent 
marked	 increase	 (3	U)	 of	 skin	 surface	 pH	 that	 can	 last	 for	 almost	
two hours,[80] and an elevated pH is detrimental on epidermal barrier 
function.[34]	It	is	of	note	that	AD‐affected	patients	have	a	higher	skin	
surface pH than individuals with normal skin.[32] Whether the preva‐
lent	cutaneous	dysbiosis	of	AD	patients	is	a	cause	or	a	consequence	
of the elevation of skin pH is not yet clarified. It is interesting though 
that topical application of a probiotic strain, Lactobacillus johnsonii, 
for 3 weeks was shown to be effective in reducing Staphylococcus 
aureus	colonization	and	improving	symptoms	of	AD	patients,[13] and 
metabolites	of	Lactobacilli	may	reduce	skin	surface	pH.
In this context, we have to mention the so‐called ‘hygiene hy‐
pothesis’, according to which there is an inverse relationship be‐
tween	AD	and	an	early	exposure	to	microbial	agents.	Exposure	to	
microbes starts at birth, when the mode of delivery greatly influ‐
ences both the gut and skin microbiota of the newborn.[29]	Vaginally	
delivered infants harbour bacterial communities resembling their 
mother's	vaginal	microbiota,	with	the	dominant	species	being	of	the	
genera Lactobacillus and Prevotella, while infants born by Caesarian‐
section acquire microbial species characteristic of the mothers’ 
skin surface, dominated by Staphylococcus, Corynebacterium and 
Propionibacterium spp.[29] Caesarian‐section delivery has been asso‐
ciated with an increased risk for immune disorders, such as asthma, 
allergy and even inflammatory bowel disease.[102]	Although	there	is	
no	 clear	 correlation	between	Caesarian‐section	 and	AD,	 it	 is	 very	
likely that Lactobacilli of vaginal origin play a protective role in the in‐
fant by priming the immature immune system against pathogens like 
Staphylococcus aureus, which may have relevance in skin disorders.
No wonder then that several studies point to the importance of 
an early‐life, proper establishment of a diverse gut microbial com‐
munity	 in	 the	 prevention	 of	 AD.[12,85,117] Numerous clinical trials 
support	this	hypothesis	by	demonstrating	that	very	early‐life	 (pre‐	
and	postnatal)	probiotic	supplementation	of	 the	children	could	re‐
duce	 the	 risk	 of	 developing	 AD[2,30,56,59,61,83,118] We presume that 
Lactobacilli	have	pivotal	 role	 in	protection	against	AD,	since	under	
natural circumstances, Lactobacilli are the major microbes trans‐
mitted from mother to baby, hence it seems logical to assume that 
these	are	the	bacteria	that	serve	the	baby's	immune	system	the	best.	
Taken together, gut flora composition is probably key in the devel‐
opment of the disease.
The gut flora produces a vast amount of metabolites, which 
may enter the circulation, travelling throughout the body and af‐
fecting distant sites of the organism. This process can reach high 
levels when the epithelial barrier integrity of the gut is disrupted, 
leading to increased intestinal permeability, a condition called as 
the "leaky gut syndrome."[68] When a "leaky gut" develops, the 
penetration of immunogenic molecules, including dietary antigens, 
bacterial toxins and pathogens increases. These antigens may ac‐
cumulate in the skin, may disturb the epidermal barrier, leading 
to chronic skin inflammation and continuous immune response.[68] 
For example, the bacterial metabolites, free phenol and para‐
cresol, are considered as biomarkers of an imbalanced gut flora, 
since the production of these molecules is triggered by infection 
of the pathogen Clostridium difficile after antibiotic treatment.[24] 
These metabolites can access the blood stream and accumulate in 
the skin.[78] Data suggest that phenol and para‐cresol can disrupt 
epidermal barrier integrity by reducing the expression of keratin 
10 in keratinocytes.[78] It has been demonstrated that daily intake 
of the probiotic Bifidobacterium breve together with the prebiotic 
galactooligosaccharide reduced serum total phenol levels and 
improved skin hydration in healthy adult women.[78] Besides, a 
randomized	double‐blind	placebo‐controlled	clinical	study	demon‐
strated that oral supplementation with a probiotic Lactobacillus 
paracasei strain decreased skin sensitivity and increased barrier 
function in the treated group,[49] pointing to the importance of oral 
probiotics in skin health.
The gut microbiota and their metabolites can affect the intestinal 
barrier function.[79] Therefore, gut dysbiosis may disturb the intes‐
tinal barrier in a way that unwanted immunogens, such as bacterial 
products, could escape the lumen and influence the state of the 
skin. We are aware that it is speculative to make direct association 
between	gut	dysbiosis,	a	"leaky	gut"	and	AD.	However,	there	is	evi‐
dence	in	the	literature	that	intestinal	permeability	is	increased	in	AD	
patients compared to control subjects.[69] We do not know whether 
it is a consequence of a gut dysbiosis in patients, but there are some 
suggestive data in the literature.
The	 short‐chain	 fatty	 acids	 (SCFAs),	 such	 as	 butyrate,	 propi‐
onate, acetate and lactate, are products of fibre fermentation by 
the gut microbiota,[71]	and	SCFAs	are	known	to	promote	epithelial	
barrier integrity of the gut and exert anti‐inflammatory effects.[71] 
Intriguingly,	 intestinal	 dysbiosis	 has	been	demonstrated	 in	AD	pa‐
tients by the analyses of their faecal samples, and a clear reduc‐
tion	 of	 SCFAs	 has	 been	 detected.[93,107] Therefore, it is tempting 
to	 hypothesize	 that	 any	 agent,	 able	 to	 influence	 gastrointestinal	
microbiota	and	the	production	of	SCFAs,	might	be	expected	to	af‐
fect inflammatory responses, which may also affect skin condition. 
Butyrate is mainly produced by species belonging to the Firmicutes 
phylum, such as Roseburia intestinalis, Faecalibacterium prausnitzii 
and Eubacterium hallii.[64] Propionate originates mainly from the pro‐
duction by species of the Bacteroidetes phylum, involving Bacteroides 
uniformis, Prevotella copri, and by Akkermansia muciniphila of the 
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Verrucomicrobia phylum.[64,75] With the use of probiotics, we may 
restore	 a	 healthy	 gut	 flora	 and	 increase	 the	 ratio	 of	 SCFA‐secret‐
ing	 bacteria	 in	 the	 gastrointestinal	 tract	 in	 AD	 patients.	 Indeed,	
according to a recent report, five doses of a cocktail containing 5 
Lactobacillus and 5 Enterococcus probiotic strains were successful 
in significantly enhancing the microbial diversity and consequently 
SCFAs	 production	 in	 the	 gut.[81] Furthermore, probiotics can also 
promote epithelial barrier integrity by inducing mucus production 
[67] and tight junction function.[101]
Among	 the	 bacterial	 metabolites	 in	 the	 colon,	 secondary	 bile	
acids	 (such	 as	 litocholic	 acid	 and	 deoxycholic	 acid)	may	 also	 have	
impact on skin physiology.[77,95] The most important secondary bile 
acid‐producing bacteria belong to the Bacteroidetes and Firmicutes 
phyla.[95] It has been reported that a Firmicutes species, Clostridium 
scindens, confers resistance against Clostridium difficile infection 
in a secondary bile acid‐dependent manner,[18] which affects skin 
function as it was discussed above. Besides, litocholic acid has been 
reported to influence adaptive immune response by affecting the 
activation of Th1 cells.[90] In this fashion, replenishing bacteria capa‐
ble of the biosynthesis of secondary bile acids may contribute to the 
maintenance of skin homeostasis. Currently, we do not know bacte‐
ria with probiotic characteristics that could do that, but these data 
could be used to develop targeted probiotics to manipulate intestinal 
bile acid metabolism.
Diet	may	affect	the	development	of	AD	across	the	gut‐skin	axis.	
Dietary gluten can damage the intestinal barrier leading to a leaky 
gut, even in individuals that do not suffer from coeliac disease.[115] It 
is of note that both coeliac [11] and non‐coeliac[14] gluten sensitivity 
have been associated with severe cutaneous manifestations resem‐
bling	AD.	Of	further	importance,	gluten	sensitivity	has	been	linked	
to intestinal dysbiosis,[25] and certain probiotics have been found to 
be	able	to	hydrolyze	gluten	polypeptides.[25] Therefore, the use of 
probiotics	as	an	adjuvant	therapy	in	gluten	sensitivity‐associated	AD	
seems to be an interesting approach.
Another	intriguing	piece	of	the	puzzle	is	the	demonstration	that	
low	vitamin	D	 level	 seems	 to	 correlate	with	 the	 severity	 of	AD.[5] 
It is of great significance that the gut microbiota may regulate sys‐
temic vitamin D metabolism,[15] and the vitamin D pathway might be 
an important signalling mechanism between the microbiota and the 
host.[65] Hence, we might assume that low vitamin D levels observed 
in these patients may be a consequence of a dysbiosis in their gut. 
Interestingly, a study performed on cystic fibrosis patients suggests 
that vitamin D deficiency of patients is associated with alterations 
in microbiota composition that may promote inflammation and that 
supplementation with vitamin D has the potential to impact micro‐
biota composition.[57] Moreover, growing body of evidence suggests 
that probiotics can increase serum levels of vitamin D and expres‐
sion of vitamin D receptor, protecting against gastrointestinal in‐
flammation.[104] These data definitely warrant investigations on the 
effects	of	probiotics	on	vitamin	D	homeostasis	in	case	of	AD.
The multifaceted interactions between the gut microbiota and 
AD	skin	clearly	point	out	 that	modulation	of	 the	gut	 flora	may	be	
utilized	 as	 adjuvant	 therapy	 in	 disease	 management.	 This	 is	 also	
supported by the growing literature about the beneficial effects of 
probiotics	on	AD,	overviewed	in	[91]. In order to better exploit pro‐
biotics	 in	AD,	better	characterization	of	 their	gut	microbiota	com‐
position and metabolome is necessary. Besides, carefully designed 
clinical investigations are required, because the studies conducted 
so far with oral probiotics are highly heterogeneous. The enrolled 
subjects, the probiotic strains used, the formulation of the probiot‐
ics, and the timing and duration of the probiotic intervention vary 
between the studies. Therefore, comprehensive studies are needed 
to assess clinical applicability.
1.2 | Psoriasis
Psoriasis is an immune‐mediated inflammatory skin disease, the 
pathogenesis of which involves numerous environmental and internal 
factors.[89] Psoriatic lesions are characteristic of the hyperprolifera‐
tion of keratinocytes with a consequent keratinocyte hyperplasia.[8] 
Ample	data	point	to	the	critical	role	of	the	cytokine	network	of	Th17	
cells in the pathogenesis of the disease.[66,84] Psoriasis has been as‐
sociated with gut dysbiosis.[51]	 It	 is	 of	note	 that	SCFAs	potentially	
regulate the generation and function of Th17 cells,[87] and the loss or 
depletion of Faecalibacterium prausnitzii, a major source of the pro‐
tective	SCFAs	in	the	gut,	is	associated	with	psoriasis,[35] suggesting a 
link	between	gut	dysbiosis,	SCFAs	and	Th17‐mediated	inflammation	
in the pathomechanism of the disease.
The development of psoriasis often accompanies gastrointes‐
tinal	 inflammation,	 such	 as	 inflammatory	 bowel	 disease	 (IBD),[53] 
the aetiology of which is closely associated with the dysbiosis of 
the gut.[50] Moreover, the reduction in bacterial diversity of the gut 
found in psoriatic patients strongly resembles the pattern of dysbi‐
osis observed in cases of IBD.[99]	Besides,	similarly	to	AD,	psoriasis	
has also been associated with low vitamin D levels, both in children 
and adults.[94]
Taken together, these data suggest the significance of the gut‐
skin axis in the pathophysiology of psoriasis and raises the relevance 
of the application of oral probiotics in the management of the dis‐
ease. To date, only three studies have looked into the effects of 
orally administered probiotics on psoriasis, using three distinct pro‐
biotic species affecting distinct pathways of the pathomechanism of 
psoriasis.[19,48,116]	All	three	studies	have	shown	improvement	in	the	
course of the disease. However, as the available data are limited and 
heterogeneous, it would be difficult to suggest a proper supplemen‐
tation protocol with probiotics in psoriasis‐affected patients.
1.3 | Rosacea
Rosacea	is	a	chronic	inflammatory	skin	disease	characterized	by	ery‐
thema and telangiectasia predominantly on the face.[17]	An	associa‐
tion between gastrointestinal microbial status and rosacea has been 
postulated, in particular the role of Helicobacter pylori infection has 
long been suggested in the pathogenesis of rosacea.[92]	Like	psoriasis,	
rosacea was associated with IBD.[33] However, the pathogenic role of 
intestinal dysbiosis in rosacea is a debated issue, and comprehensive 
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studies	are	missing.	A	recent	Korean	metagenomic	study	observed	a	
link between intestinal microbial alterations and rosacea in a group 
of 12 Korean women with rosacea[82] Besides, a case study reported 
an effective treatment of one rosacea affected patient with a com‐
bination of orally administered doxycycline and probiotics,[42] which 
might give us a hint about the potential of oral probiotics in rosacea 
management.
1.4 | Acne vulgaris
Acne	vulgaris	is	a	disease	of	the	pilosebaceous	unit,	manifesting	in	
non‐inflammatory comedones or inflammatory pustules and pap‐
ules.	The	pathophysiology	of	acne	is	characterized	by	sebum	over‐
secretion,	follicular	hyperkeratinization	and	increased	production	of	
pro‐inflammatory cytokines.[10]	Acne	is	quite	commonly	associated	
with microbial dysbiosis.
One of the most investigated subjects in acne studies is the role 
of a commensal cutaneous bacterium, Cutibacterium acnes	(C. acnes, 
reclassified from Propionibacterium acnes as proposed in [100]	)	in	the	
pathogenesis of acne, which is still not fully elucidated. C. acnes is a 
predominant species of the skin microbiota and an important pro‐
ducer	of	SCFAs	on	skin	surface;	hence,	C. acnes is essential in the 
maintenance of skin homeostasis.[20] Nevertheless, C. acnes can also 
act as an opportunistic pathogen.[96] It was a long‐standing theory 
that an increased sebum and fatty acid production favours the pro‐
liferation of C. acnes in the hair follicles and associated sebaceous 
glands, which induces the production of inflammatory mediators.[10] 
However, the most recent findings on C. acnes suggest that it is not 
the proliferation of the bacterium, rather the presence of certain C. 
acnes phylotypes that determines acne onset,[31] as no quantitative 
difference of C. acnes abundance between acne patients and healthy 
individuals has been found.[31]	Phylotype	IA1	was	the	most	strongly	
associated	with	acne,	while	phylotypes	IA2,	IB	and	II	were	less	rep‐
resented in acne‐affected skin.[72]
There	is	a	long‐standing	association	between	diet	and	acne.	Since	
the prevalence of acne is noticeably higher in developed countries, 
it is believed that the high glycemic or Western‐type diet triggers 
acne formation.[74,110]	 A	 high	 glycemic	 load	 drives	 the	 production	
of	insulin	and	insulin‐like	growth	factor‐1	(IGF‐1)	that	promotes	the	
proliferation of sebocytes and keratinocytes, as well as inducing lipid 
synthesis in the sebaceous glands.[27]
The	 gut	 microbiota	 has	 been	 shown	 to	 induce	 IGF‐1.[120] 
Hypothetically, we may assume that Western diet affects the gut 
flora	in	a	way	that	may	lead	to	the	increased	induction	of	the	IGF‐1	
pathway.	Adding	to	the	picture,	a	recent	study	demonstrated	that	in	
the gut flora of acne patients the ratio of the phyla Bacteroidetes to 
Firmicutes increased,[26] which is consistent with the enterotype of 
the Western diet.
Interestingly, C. acnes	 has	been	 shown	 to	 stimulate	 the	 IGF‐1/
IGF‐1‐receptor	 system	 in	 the	 skin,[54] suggesting a dual activation 
of	 the	 IGF‐1/IGF‐1‐receptor	pathway	by	 the	gut	and	skin	microbi‐
ota, which may contribute to the pathophysiology of acne. Whether 
these mechanisms act independently or are interrelated needs 
further investigation. However, it is reasonable to assume that the 
two	mechanisms	act	through	a	synergistic	loop.	Gut	dysbiosis	may	
induce	IGF‐1	that	may	trigger	a	change	in	the	quantity	and/or	quality	
of the lipid‐rich sebum,[105]	which	may	favour	the	colonization	of	the	
pilosebaceous unit by distinct C. acnes phylotypes,[46] disturbing the 
tight equilibrium among members of the skin flora. This might be a 
feasible mechanism for the possible interconnectedness of gut and 
skin flora.
Other explanations for a possible causation of gut microbial im‐
balance and inflammatory acne involve the role of lipopolysaccha‐
rides	 (LPS),	 as	 LPS	 biosynthesis	 pathways	 have	 been	 found	 to	 be	
upregulated in acne patients, which may be a consequence of the 
increased	abundance	of	the	main	LPS‐producing	Bacteroidetes spe‐
cies in the intestine of the individuals.[26] In our point of view, these 
pathways	(IGF‐1	and	LPS	pathways)	are	possibly	not	independent	of	
each	other.	Even	if	there	is	still	no	direct	evidence	that	gut	dysbio‐
sis contributes to the pathogenesis of acne, the association seems 
to be clear, and suggest the relevance of a probiotic‐based supple‐
mental	therapy	in	acne	treatment.	Supporting	this	theory,	one	study	
demonstrated that the consumption of the probiotic Lactobacillus 
rhamnosus SP1 for 12 weeks resulted in a decreased expression of 
IGF‐1	in	the	skin,	and	in	an	improvement	of	acne	symptoms.[37]
1.5 | Other skin diseases
In addition to those common disorders detailed above, we would 
also like to draw the readers’ attention to some less common, though 
more serious skin pathologies, including hidradenitis suppurativa 
(HS),	 erythema	 nodosum	 (EN)	 and	 pyoderma	 gangrenosum	 (PG).	
These disorders are frequently associated with intestinal inflamma‐
tion, such as IBD.[40] Their aetiology is complex, and not fully clari‐
fied.	So	far,	a	correlation	between	these	diseases	and	gut	dysbiosis	
has not been made,however, the common association with IBD raises 
the possibility of the involvement of a disturbed gut microbiome in 
their pathogenesis. The beneficial effects of probiotics on IBD have 
been suggested,[1] but data of the effects of probiotics on the occur‐
rence of cutaneous manifestations in IBD patients is missing. The 
only study evaluating the association between probiotic use and 
skin lesions in IBD patients has been published very recently, and it 
demonstrates a negative correlation between the use of probiotics 
and the occurrence of skin lesions,[98] prompting the importance of 
research to be made in this direction. In addition, it would be very 
intriguing	to	see	the	gut	microbial	status	of	HS‐,	EN‐	or	PG‐affected	
patients without IBD.
2  | CONCLUSIONS
We outlined here a framework of how an imbalanced gut flora may 
contribute to the development of inflammatory skin diseases, and we 
propose a scheme of the benefits of probiotic intervention on these 
disorders	(illustrated	on	Figure	1).	We	are	aware	that	inflammatory	
skin conditions are all multifactorial diseases, the pathophysiology 
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of which cannot be simplified solely to the disruption of the gut mi‐
crobiota. Nonetheless, a disturbance in the homeostasis of the gut 
flora may contribute to the development and symptoms of these pa‐
thologies.	As	a	logical	continuation	to	these,	oral	probiotics	have	an	
obvious	translational	potential	in	dermatology.	Since	adverse	effects	
have not been recorded in relation with the application of oral probi‐
otics, we think that probiotic supplementation could be a cheap and 
simple modality in the management of skin diseases.
For the sake of completeness of the concept of probiotic appli‐
cation, we have to mention that the concept of probiotics has been 
re‐examined since the now widely adopted definition by the WHO 
that we also cited in the introduction. In 2013, The International 
Scientific	 Association	 for	 Probiotics	 and	 Prebiotics	 (ISAPP)	 orga‐
nized	a	panel	meeting	to	define	clearer	guidelines	and	standards	for	
using of probiotics, and for the determination of what products can 
be included in the scope of probiotics.[52] The panel proposed a slight 
modification of the original 2001 definition, that is, probiotics are 
‘live microorganisms that, when administered in adequate amounts, 
confer a health benefit on the host’. It is important that this defini‐
tion differentiates between commensal microorganisms and probi‐
otics.	Although	probiotics	are	usually	derived	from	gut	commensals,	
until	these	strains	are	properly	characterized	and	their	health	effects	
are	clearly	demonstrated,	they	cannot	be	called	'probiotics'.[52] It is 
important to adopt the criteria defining probiotics to avoid the mis‐
leading of consumers and researchers, resulting from the misuse of 
the term in the absence of proved health effects.
There are many outstanding questions as for the mechanism of 
action	of	probiotics	yet	to	be	answered.	Even	though	we	outlined	sev‐
eral pathways where probiotics could interfere with the gut‐skin axis 
modulating host immune and metabolic processes, further studies are 
required to uncover their exact mechanisms of action.
An	 issue	 with	 probiotic	 supplementation	 is	 that	 the	 coloniza‐
tion of probiotic bacteria in the gut is mostly transient as they are 
only detectable for less than 2 weeks after cessation of intake.[39,43] 
Researchers tried to answer the question of what may determine 
the	successful	colonization	by	a	given	species.	It	has	been	suggested	
that it lies with the ability of the probiotic to adapt to the ecosys‐
tem of the gut, which is determined by intestinal phylogenetic 
limiting and resource availability in the individual.[70] The study by 
Maldonado‐Gómez	et al demonstrated that a certain Bifidobacterium 
longum	(B. longum)	strain	was	able	to	persist	for	over	6	months	in	a	
subset of subjects in whom that was originally absent. Moreover, 
the persistent B. longum bacteria enriched the faecal microbiome 
with functional genes associated with B. longum.[70] This study pro‐
vides an important discovery which can be helpful in the prediction 
of the outcome of supplementation with a specific bacterial strain, 
which	could	be	used	in	the	personalized	application	of	probiotics.
Additionally,	it	also	needs	clarification	whether	and	how	the	ma‐
nipulation of the gut microbiome affects the microbiome of the skin. 
Given	the	delicate	nature	of	the	interaction	between	host	and	the	
microbiome to maintain the homeostasis of the human organism, 
we	presume	that	the	different	microbial	communities	(eg	gut,	skin,	
oral,	vaginal)	should	not	be	considered	as	separate,	but	rather	as	a	
complex, interacting ecosystem of the commensals inhabiting dis‐
tinct body regions. In the above‐described skin diseases, bacterial 
dysbiosis may not be restricted to the gut, but communities at dis‐
tant body sites could also be affected. Therefore, modulation of the 
gut microbiota by the application of oral probiotics may impact upon 
the skin microbiota, as well. In this regard, it is an intriguing issue 
whether this plausible interaction between the gut and skin micro‐
biota is uni‐ or bidirectional. Hypothetically, the synthesis of vitamin 
D	in	the	skin	upon	UV	irradiation	might	be	exploited	as	adjunctive	
in case of gastrointestinal inflammation, such as IBD, where vitamin 
D deficiency occurs.[114] These are fascinating fields of microbial re‐
search yet to be explored.
This line of research though has to face many challenges. For 
one, the skin flora is considered to be highly diverse and variable.[47] 
There are topographical differences on different body sites that 
allow	only	a	certain	set	of	microbes	to	colonize	certain	skin	regions.	
More importantly, there are many individual‐specific factors, includ‐
ing sex, age, occupation, clothing, the usage of hygienic products 
that determine the variability seen in the cutaneous flora.[47,109] The 
aforementioned factors create an individual‐specific micro‐envi‐
ronment	on	the	skin	that	may	require	personalized	solutions	for	the	
management of any skin conditions with oral probiotics.
A	major	area	 in	 this	 subject,	which	surpasses	 the	capacity	of	
the current essay, is the translational potential of the use of topical 
probiotics, oral and topical prebiotics or the combination of pre‐ 
and probiotics, called synbiotics, for the manipulation of micro‐
bial communities. The use of topical probiotics may have special 
subclinical significance, for example to improve skin defense with 
probiotic‐containing cosmeceuticals. It has been reported that 
B. longum strains exert pro‐differentiating and pro‐regenerating 
effects on primary human epidermal keratinocytes.[111] However, 
F I G U R E  1  A	proposed	scheme	of	the	contribution	of	a	dysbiotic	
gut to the onset of cutaneous inflammation, highlighting the 
potential sites of action of probiotic intervention that may result in 
the alleviation of the inflammatory condition
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topical applications of probiotics can create challenges, not only 
because of the problem of proper formulation, but also the envi‐
ronmental	conditions	of	the	skin	that	may	prevent	colonization	by	
the probiotic.[113] It seems probable though that using the most 
suitable oral probiotic strain in combination with topical probiotics 
and/or	prebiotics	might	help	in	the	individualized	design	of	treat‐
ment of skin disorders.
To better exploit the potential within oral probiotics in derma‐
tology,	clinical	trials	should	be	conducted	in	order	to	optimize	the	
intervention protocols involving the determination of the optimal 
formulation of the most effective probiotic strain or the combi‐
nation of certain strains, the duration of the supplementation or 
treatment, and also the inclusion criteria of the subjects in the 
study.
The described diseases are all common, affecting a substantial 
proportion	of	the	population	of	developed	countries.	Even	though	
their	pathomechanisms	are	getting	well	characterized,	effective	and	
well‐tolerated treatment modalities are currently lacking. Oral probi‐
otic supplementation is relatively cheap and if proven to be effective, 
it could serve as a useful, supportive therapy for the management 
of microbiome‐associated cutaneous disorders. Our opinion is that 
both gastroenterology and dermatology should better understand 
the translational potential of the gut‐skin axis for the perks of a bet‐
ter therapeutic strategy.
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